Navigation Links
Cephalon Reports Strong First Quarter Earnings
Date:5/1/2008

y. Adjusted net income guidance is $346-$353 million and basic adjusted income per common share guidance is $5.10-$5.20.

For the second quarter of 2008, Cephalon is introducing sales guidance of $455-$465 million, adjusted net income guidance of $74.6-$81.4 million and basic adjusted income per common share guidance of $1.10-$1.20.

Basic adjusted income per common share guidance for both the second quarter 2008 and full-year 2008 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's second quarter 2008 performance in a conference call with investors beginning at 5:00 p.m. U.S. EDT today. To participate in the conference call, dial +1-913-981-5581 and refer to conference code number 7561641. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information," then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs close to 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide), AMRIX, TREANDA, VIVITROL(R) (naltrexone for extended-release injectable suspen
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cephalon Appoints Gerald J. Pappert as General Counsel
2. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
3. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
4. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
7. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
8. Nu Skin Enterprises Reports First-Quarter 2008 Results
9. Cardinal Health Reports Third Quarter Results
10. BioMed Realty Trust Reports First Quarter 2008 Financial Results
11. Cardiac Science Reports Strong Q1 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 TayganPoint Consulting Group, a ... President and co-founder John Cassimatis was named as ... for 2014, recognizing the region’s top healthcare and ... executive of the year. , The Innovation Awards ... that continue to shape the medical industry in ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... York, New York (PRWEB) September 18, 2014 ... ) continue to mount in U.S. courts, Bernstein ... has recommended that the U.S. Food & Drug ... new restrictions that, if implemented, could greatly reduce ... Bone, Reproductive and Urologic Drug Advisory Committee, and ...
(Date:9/18/2014)... News) -- Teens and young adults who,ve been mentored ... provides them with greater responsibility and independence early on ... "We found that having a mentor provides a clear ... author, Steve McDonald, an associate professor of sociology at ... release. In conducting the study, published online ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News: Mentors May Steer Young People Toward More Rewarding Careers 2
... approach to treatment that focuses on recovery from mental ... acclaim for the Medical College of Georgia Department of ... Project GREAT, or the Georgia Recovery-Based Educational Approach ... to be part of their own care, while also ...
... FRIDAY, Feb. 24 (HealthDay News) -- Sudden Infant Death Syndrome ... German researchers reports. DNA analysis from a small group ... the male children carried a particular enzyme mutation that may ... the case for female SIDS patients. Study author Dr. ...
... Overweight or obese people with chronic kidney disease may suffer ... new study warns. Cleveland Clinic researchers analyzed the eating ... who took part in the U.S. National Health and Nutrition ... percent said they had tried to lose weight in the ...
... Serena Gordon HealthDay Reporter , FRIDAY, Feb. 24 ... on their own take a companion -- usually a spouse ... office visits, researchers report. And they tend to bring ... health care system with another important member of a patient,s ...
... , This release is available in Spanish ... and the university hospital Virgen de las Nieves in Granada ... toxic than that traditionally used and only targets cancerous tissue. ... efficient cancer postoperative treatment for cases of cancer of the ...
... Cells that die naturally generate a lot of internal debris ... leading to diseases such as lupus., Now Georgia Health Sciences ... a woman,s immune system from attacking a fetus also helps ... such as DNA or joints. , The findings point ...
Cached Medicine News:Health News:Psychiatry program garners national education award 2Health News:Psychiatry program garners national education award 3Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 2Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 3Health News:Dieting Can Prove Dangerous for Kidney Disease Patients 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 3Health News:A new radiotherapy technique significantly reduces irradiation of healthy tissue 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3
(Date:9/18/2014)... BCC Research report discusses the medical device technologies in terms ... and opportunities for different devices and regions. It includes forecasts ... the report focuses on technological trends in recent years in ... and Japan . Use ... device technologies market. - Analyze market structure, including segments and ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... has updated the incredibly successful Serialisation Countdown calendar to ... PDF, available at pharmaserialisation.com shows the serialisation ... they will be coming into force. For ... a matter of "if", but "when" they will have ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Trial Marks Third Study in Company,s STEALTH C Clinical Program ... Nitazoxanide in the Treatment of Chronic Hepatitis C, ... company, today announced that it has begun enrolling,patients in a ... hepatitis C. Preliminary data from the study is,expected in the ...
... 17 BrainCells Inc. (BCI), a,biopharmaceutical company utilizing ... promote the growth of new neurons for the ... that it has,initiated a Phase 2a clinical trial ... of depression with anxiety., "We are encouraged ...
Cached Medicine Technology:Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 2Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 3BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety 2
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: